Presentation on AMIRST Acute Myocardial Infarction Study and Pediatric Allogeneic Mismatched Bone Marrow Transplant Program
RANCHO CORDOVA, Calif. and LOS ANGELES, Oct. 10, 2013 (GLOBE NEWSWIRE) — TotipotentRX Corporation and ThermoGenesis Corp. (Nasdaq:KOOL) today announced two upcoming presentations at a pre-conference symposium of the American Association of Blood Banks Annual Meeting in Denver, CO on Sunday, October 13th at 1:30 pm (MDT). The first presentation will be initial results data from TotipotentRX’s 24 month case study (Pilot Safety Trial) using its stem cell combination product AMIRST therapy in patients with acute myocardial infarction. The second presentation will be given on the post-transplant survival and engraftment rates of pediatric patients receiving mismatched (allogeneic) bone marrow transplants processed with the ThermoGenesis MXP® MarrowXpress® stem cell processing technology. The presentations will be given by Kenneth Harris, Study Director and CEO of TotipotentRX.
In July 2013, ThermoGenesis and TotipotentRX entered into a definitive merger agreement to form Cesca Therapeutics, and ThermoGenesis is planning to file its Registration Statement on Form S-4 within three to four weeks. Upon approval by shareholders of both companies and meeting other conditions, Cesca Therapeutics will be a leading autologous cell therapeutics company, having three lead therapy candidates in Phase I/II and II/III stages in cardiovascular and orthopedic diseases.